angiotensin IV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
In many ectomycorrhizas the Hartig net hyphae lack internal divisions, creating a multinuclear transfer cell-like structure that facilitates interhyphal transport. The hyphae have a high concentration of organelles responsible for energy and protein production (mitochondria and rough endoplasmic reticulum) at their tips. There are signs that transporters in both fungal and plant plasma membranes are active, suggesting a bidirectional nutrient exchange.
The election was a rare victory for conservatism and nationalism in Thailand, marking its first victory in the 21st century. Bhumjaithai was seen as benefiting from nationalist sentiments after Thailand's recent clash with Cambodia. While the other two major parties performed respectably, they ultimately fragmented the centrist and progressive vote. Anutin formed a coalition government with Pheu Thai and was re-elected prime minister on 19 March 2026. The conduct of the election remained subject to legal challenge, with the Constitutional Court due to rule in September 2026 on whether codes printed on the ballots breached the constitutional guarantee of voting secrecy.
Colony-forming unit-fibroblast Mesenchymal stem cell / marrow stromal cell Chondrocyte Hypertrophic chondrocyte Mesenchymal (mesoderm origin) stem cells are undifferentiated, meaning they can differentiate into a variety of generative cells commonly known as osteochondrogenic (or osteogenic, chondrogenic, osteoprogenitor, etc.) cells. When referring to bone, or in this case cartilage, the originally undifferentiated mesenchymal stem cells lose their pluripotency, proliferate and crowd together in a dense aggregate of chondrogenic cells (cartilage) at the location of chondrification. These chondrogenic cells differentiate into so-called chondroblasts, which then synthesize the cartilage extracellular matrix (ECM), consisting of a ground substance (proteoglycans, glycosaminoglycans for low osmotic potential) and fibers. The chondroblast is now a mature chondrocyte that is usually inactive but can still secrete and degrade the matrix, depending on conditions. Cell culture studies of excess Vitamin B inhibits the synthesis of chondroitin sulfate by chondrocytes and causes the inhibition of chondrogenesis in the developing embryo which may result in limb malformations. Chondrocytes undergo terminal differentiation when they become hypertrophic, which happens during endochondral ossification. This last stage is characterized by major phenotypic changes in the cell.
year is the laboratory's determination of the age of the sample, in radiocarbon years range is the laboratory's estimate of the error in the age, at 1σ confidence. 'BP' stands for "before present", referring to a reference date of 1950, so that "500 BP" means the year AD 1450. For example, the uncalibrated date "UtC-2020: 3510 ± 60 BP" indicates that the sample was tested by the Utrecht van der Graaff Laboratorium ("UtC"), where it has a sample number of "2020", and that the uncalibrated age is 3510 years before present, ± 60 years. Related forms are sometimes used: for example, "2.3 ka BP" means 2,300 radiocarbon years before present (i.e. 350 BC), and "14C yr BP" might be used to distinguish the uncalibrated date from a date derived from another dating method such as thermoluminescence. Calibrated 14C dates are frequently reported as "cal BP", "cal BC", or "cal AD", again with 'BP' referring to the year 1950 as the zero date. Radiocarbon gives two options for reporting calibrated dates. A common format is "cal date-range confidence", where:
=== Long-acting === Long-acting insulin analogues are designed to provide continuous basal insulin coverage for up to 24 hours, with the exception of ultra-long-acting analogues, which work for up to a week. These include insulin glargine, insulin detemir, insulin degludec, and insulin icodec, which have been modified through amino acid substitutions and fatty acid conjugation to alter their subcutaneous absorption and extend their duration of action. A key feature of long-acting insulin analogues is reversible albumin binding and di-hexamer formation, which slow insulin dissociation and provide a more stable pharmacokinetic and pharmacodynamic profile, reducing glycemic fluctuations and nocturnal hypoglycemia. Insulin glargine (100 U/mL), first approved by the US Food and Drug Administration (FDA) in 2000 and marketed as Lantus, forms zinc-mediated hexamer aggregates after injection, resulting in a slow insulin release. In 2015, a higher-concentration formulation (300 U/mL), marketed as Toujeo, was introduced, offering up to 36-hour coverage and a lower risk of nocturnal hypoglycemia. Insulin detemir, approved in 2005 as Levemir, features a C14 fatty acid modification at lysine B29, promoting di-hexamer formation and albumin binding for an extended duration. While effective, insulin detemir often requires twice-daily dosing for optimal glycemic control.
Sources: en.wikipedia.org
==== Abkhaz attack ==== With respect to the war's second theater, the report found the joint Abkhaz-Russian attack on the Kodori Gorge was unjustified under international law and was an illegal use of force. The commission noted that the Abkhaz preparation of military operation in the upper Kodori Valley was acknowledged by the Russian officials and Abkhaz deployment in the lower Kodori Valley "reportedly" began already on 6 August 2008. According to the commission, since "the upper Kodori Valley did not belong to Abkhaz-controlled territory under the provisions of the Moscow Agreement", the attack "must therefore be qualified as use of force prohibited by Art. 2(4) of the Charter and moreover as an “armed attack” on Georgia in the sense of Art. 51 of the UN Charter." The commission said Russian support of Abkhazia "could not be justified as collective self-defence in favour of Abkhazia, because third-party involvement in an internal military conflict in support of the seceding party is not allowed". The commission concluded: "The use of force by Abkhazia was not justified under international law and was thus illegal. The same applies to the Russian support for Abkhaz use of force." General Russian involvement in the conflict in Georgia was "a violation of the fundamental international legal prohibition of the use of force."
=== Patient support === Burn patients require support and care – both physiological and psychological. Respiratory failure, sepsis, and multi-organ system failure are common in hospitalized burn patients. To prevent hypothermia and maintain normal body temperature, burn patients with over 20% of burn injuries should be kept in an environment with the temperature at or above 30 degree Celsius. Metabolism in burn patients proceeds at a higher than normal speed due to the whole-body process and rapid fatty acid substrate cycles, which can be countered with an adequate supply of energy, nutrients, and antioxidants. Enteral feeding a day after resuscitation is required to reduce risk of infection, recovery time, non-infectious complications, hospital stay, long-term damage, and mortality. Controlling blood glucose levels can have an impact on liver function and survival. Risk of thromboembolism is high and acute respiratory distress syndrome (ARDS) that does not resolve with maximal ventilator use is also a common complication. Scars are long-term after-effects of a burn injury. Psychological support is required to cope with the aftermath of a fire accident, while to prevent scars and long-term damage to the skin and other body structures consulting with burn specialists, preventing infections, consuming nutritious foods, early and aggressive rehabilitation, and using compressive clothing are recommended.
After this, the June Days uprising broke out, over the course of 24–26 June, when the eastern industrial quarter of Paris, led by the worker Louis Pujol, fought the western quarter, led by general Louis-Eugène Cavaignac, who had been appointed military dictator. The socialist party was defeated and afterwards its members were deported. But the republic had been discredited and had already become unpopular with both the peasants, who were exasperated by the new land tax of 45 centimes imposed in order to fill the empty treasury, and with the bourgeoisie, who were intimidated by the power of the revolutionary clubs and disadvantaged by the economic stagnation. By the "riots" of the June Days, the working classes were also alienated from it. The Duke of Wellington wrote at this time, "France needs a Napoleon! I cannot yet see him..." The granting of universal suffrage to a society with Imperialist sympathies would benefit reactionaries, which culminated in the election of Louis-Napoléon Bonaparte as president of the republic.
The Greenspan lab was also involved in studies showing that mutations that affect the protease BMP-1 underlie some cases of osteogenesis imperfecta (brittle bone disease), and showing molecular mechanisms involved.
== Further reading == Videos "Why Is McDonald's Struggling In The Philippines? Jollibee". CNBC. November 20, 2018. Archived from the original on November 6, 2021. "Jollibee CEO on the homegrown fast food giant's growing appetite for acquisitions". CNBC International TV. May 7, 2019. Archived from the original on October 2, 2020. Retrieved May 7, 2019.{{cite web}}: CS1 maint: bot: original URL status unknown (link) "Why Jollibee's Fast Food has Americans Waiting in Insane Lines — Cult Following". Eater/Vox Media. April 13, 2017. Archived from the original on November 6, 2021. "Jollibee: How it became one of the world's biggest Asian fast food companies". South China Morning Post. July 20, 2019. Archived from the original on November 6, 2021.
Sources: en.wikipedia.org
The term RAST became a colloquialism for all varieties of (in vitro allergy) tests. This is unfortunate because it is well recognized that there are well-performing tests and some that do not perform as well, yet they are all called RASTs, making it difficult to distinguish between them. For these reasons, it is now recommended that the use of RAST as a generic descriptor of these tests be abandoned. The updated version, the ImmunoCAP Specific IgE blood test, is the only specific IgE assay the Food and Drug Administration has approved to quantitatively report to its detection limit of 0.1 kU/L.
The first tubeless automated insulin delivery system, Omnipod 5 uses SmartAdjust technology to actively predict glucose levels up to 60 minutes ahead and adjust insulin delivery every 5 minutes—automatically increasing, decreasing, or pausing basal insulin—towards a user‑customizable glucose target. The system integrates with several continuous glucose monitors: Dexcom G6, Dexcom G7, and Freestyle Libre 2 Plus. Omnipod 5 is FDA‑cleared for people with type 1 diabetes aged 2 years and older, and adults with type 2 diabetes aged 18+. The Omnipod 5 became available through the NHS in the UK in 2023 in limited areas, and in 2024 the NHS announced the gradual rollout of Hybrid Closed Loop systems to all type 1 diabetes patients in England over the next 5 years, including the Omnipod 5.
First observations of short-lived pear-shaped atomic nuclei Research conducting using the Miniball experimental setup found evidence of pear-shaped heavy nuclei, in particular radon-220 and radium-224. These results were named in the Institute of Physics (IoP) "top 10 breakthroughs in physics" in 2013, and was featured as the cover of Nature 2013. In 2020, due to the HIE-ISOLDE upgrade, radium-222 was also found to have a "stable pear shape". Laser spectroscopy has been performed on a short-lived radioactive molecule, containing radium, which further studies into could reveal physics beyond the Standard Model due to time-reversal symmetry breaking. Measurement of 229mTh transition energy In 2023, ISOLDE made the first 1%-level measurement of the ultralow-energy thorium-229m nuclear isomer, detecting photons at an energy of 8.338±0.024 eV. This was a key step in the construction of a future nuclear clock. Below is a list of improvements needed for the ISOLDE facility, considering both medium and long-term goals. Some of these improvements have been proposed by the EPIC project.
== Predicted properties == Very few properties of bohrium or its compounds have been measured; this is due to its extremely limited and expensive production and the fact that bohrium (and its parents) decays very quickly. A few singular chemistry-related properties have been measured, but properties of bohrium metal remain unknown and only predictions are available.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.